U.S. Markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.14+0.13 (+0.33%)
At close: 4:00PM EST

39.14 0.00 (0.00%)
After hours: 4:03PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close39.01
Open39.75
Bid33.34 x 900
Ask40.05 x 800
Day's Range38.35 - 39.75
52 Week Range12.09 - 40.71
Volume791,185
Avg. Volume870,444
Market Cap3.987B
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-2.60
Earnings DateFeb 23, 2021 - Mar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.22
  • Top 10 Healthcare Stocks To Buy for the Future
    Insider Monkey

    Top 10 Healthcare Stocks To Buy for the Future

    In this article we present the list of Top 10 Healthcare Stocks To Buy for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future. Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market. All it takes is one blockbuster […]

  • Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
    PR Newswire

    Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 8:00 a.m. ET.

  • Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
    PR Newswire

    Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

    Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFBE). Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of NCFBE and other inflammatory diseases.